On March 3, 2015, the state endorsed funding for a $265M multidisciplinary research building at UK.
Press conference announcing Dr. Wermeling's naloxone nasal spray Fast Track designation from the FDA.
A nasal spray of the anti-opioid drug naloxone, developed by Daniel Wermeling, has FDA fast-track designation.
Thorson published findings on a new antibiotic derived from a soil bacterium from a KY coal fire.
